Sponsor contract loss or non-renewal
Revenue depends on ongoing clinical programs, so cancellations or delays can quickly reduce utilization and backlog conversion.
- Scope
- Biopharma and device sponsor relationships
- Materiality
- high
Medpace Holdings, Inc.
Medpace Holdings is a contract research organization that runs outsourced clinical development programs for biotechnology, pharmaceutical, and medical device companies. It provides full-service Phase I-IV trial support, combining therapeutic expertise, regulatory input, and global trial operations to help sponsors move products through development faster and more efficiently.
22,2 %
17,8 %
+20,0 %
0.74
0.74
| % | |
|---|---|
| Full-service clinical development | 85% End-to-end outsourced clinical trial services spanning Phase I through Phase IV. |
| Therapeutic expertise and study consulting | 10% Scientific, medical, and regulatory support embedded into trial planning and execution. |
| Operational and site management services | 5% Patient enrollment, investigator recruitment, and global trial coordination services. |
Medpace sells primarily to biotechnology, pharmaceutical, and medical device sponsors that outsource clinical...
- Small and mid-sized biopharmaceutical companiesprimary
They buy full-service clinical development because they often lack the internal infrastructure to run global trials efficiently.
- Biotechnology companiesprimary
They outsource trial design, site management, and execution to accelerate development and conserve internal capital.
- Pharmaceutical companiessecondary
They use Medpace for selected programs and therapeutic-area expertise when they need external trial capacity.
- Medical device companiessecondary
They buy regulated clinical research services for device studies and related development programs.
Medpace operates globally, with approximately 6,200 employees across 46 countries as of year-end 2025 and about 6,000...
- •Global trial operations across 46 countries support patient access and site coverage
- •U.S. headquarters anchors sponsor relationships and corporate functions
- •International footprint improves regulatory execution and local market knowledge
- •Foreign earnings are indefinitely reinvested, indicating meaningful overseas operations
- •Country-level revenue disclosure was not provided in the excerpts
Medpace is focused on expanding share in the Phase I-IV CRO market by emphasizing full-service delivery, therapeutic...
01
Grow share in outsourced clinical developmentmedium-term
The company wants to capture more sponsor demand for full-service CRO outsourcing across the development lifecycle.
02
Deepen therapeutic specializationmedium-term
Therapeutic expertise is a key differentiator in winning complex studies and repeat business.
03
Invest in operating capacity and technologyshort-term
Facilities, equipment, and systems support trial execution quality and future growth.
Medpace is exposed to sponsor concentration, contract timing, and execution risk because revenue depends on winning and...
Fixed-fee pricing and change-order execution
If study costs exceed estimates or change orders are delayed, margins can fall because the company bears execution risk.
- Scope
- Clinical trial contracts
- Materiality
- high
Patient recruitment and investigator availability
Trials depend on enrolling patients and securing investigators, and delays can push out revenue recognition and increase costs.
- Scope
- Global clinical operations
- Materiality
- high
Cybersecurity and information system outages
Clinical operations rely on systems such as ClinTrak and sensitive sponsor data, so breaches or outages can disrupt delivery and damage reputation.
- Scope
- Operational systems and confidential trial data
- Materiality
- medium
Customer and therapeutic concentration
A limited number of large sponsors or therapeutic classes can create outsized exposure to program cancellations or class-wide setbacks.
- Scope
- Top ten customers and concentrated therapeutic areas
- Materiality
- high
International and geopolitical exposure
A broad country footprint creates exposure to local regulation, political instability, FX movements, and cross-border operating complexity.
- Scope
- 46-country operating platform
- Materiality
- medium
Revenue recognition on clinical contracts
Affects quarterly revenue, gross margin, and backlog conversion
Backlog and contract estimates
Affects revenue outlook and margin comparability
Uncertain tax positions
Can create future tax expense, interest, and penalties
Foreign earnings indefinitely reinvested
Affects tax expense and potential repatriation costs
Lease and purchase commitments
Affects liquidity disclosure and future cash requirements
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
CERO THERAPEUTICS HOLDINGS, INC.
CERO · Biological Products, (No Diagnostic Substances)
HARVARD BIOSCIENCE INC
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
NextCure, Inc.
NXTC · Pharmaceutical Preparations
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Medline Inc.
MDLN · Surgical & Medical Instruments & Apparatus
: 28/04/2026